title: Levothyroxine (LT4) suppression treatment for benign thyroid nodules alters coagulation.
abstract: OBJECTIVE
  Endogenous hyperthyroidism is associated with altered coagulation. The aim of the present study is to investigate the effect of levothyroxine (LT(4)) suppression treatment for benign thyroid nodules on coagulation system.
  
  
  METHODS
  Prospective case-control study. Patients Thirty consecutive euthyroid pre-menopausal women with nodular goitre disease and 28 healthy controls were included in the study.
  
  
  METHODS
  Plasma fibrinogen, d-dimer, von Willebrand factor (vWF), tissue factor (TF), tissue plasminogen activator (tPA), plasminogen activator inhibitor (PAI-1) and tissue factor pathway inhibitor (TFPI) levels were measured at baseline and after LT(4) suppression therapy.
  
  
  RESULTS
  Plasma levels of fibrinogen, d-dimer, vWF, TF and PAI-1 increased significantly after treatment with LT(4) for 1 year. Serum FT(4) was a significant predictor of increased fibrinogen, vWF and PAI-1 levels, when the data was controlled for age and BMI.
  
  
  CONCLUSIONS
  Our results suggest that LT(4) suppression therapy for benign thyroid nodules is associated with enhanced coagulation.
authors.affiliation: Department of Internal Medicine, Division of Endocrinology and Metabolism, Dokuz Eylul University, Izmir, Turkey.
authors.forename: Tevfik
authors.initials: T
authors.lastname: Demir
authors.forename: Baris
authors.initials: B
authors.lastname: Akinci
authors.forename: Abdurrahman
authors.initials: A
authors.lastname: Comlekci
authors.forename: Oguzhan
authors.initials: O
authors.lastname: Karaoglu
authors.forename: Mehmet Ali
authors.initials: MA
authors.lastname: Ozcan
authors.forename: Serkan
authors.initials: S
authors.lastname: Yener
authors.forename: Faize
authors.initials: F
authors.lastname: Yuksel
authors.forename: Mustafa
authors.initials: M
authors.lastname: Secil
authors.forename: Sena
authors.initials: S
authors.lastname: Yesil
mesh_terms: D000328:Adult; D001777:Blood Coagulation / Q000187:drug effects*; D016022:Case-Control Studies; D015536:Down-Regulation; D005260:Female; D005340:Fibrinogen / Q000378:metabolism; D006042:Goiter; D006801:Humans; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood; D011446:Prospective Studies; D016606:Thyroid Nodule / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D013974:Thyroxine / Q000008:administration & dosage*
chemical_list: D017395:Plasminogen Activator Inhibitor 1; D005340:Fibrinogen; D013974:Thyroxine